In8Bio Inc is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in the advancement of cell-based therapies, particularly utilizing T cell engineering to target and eliminate cancer cells. By harnessing the power of the immune system, In8Bio aims to create effective and personalized treatment options for patients with various types of malignancies. Their research and development efforts are centered around developing cutting-edge approaches that enhance the efficacy and safety of immunotherapies, contributing to the evolving landscape of cancer treatment. Read More
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
In8bio (NASDAQ: INAB) is developing groundbreaking treatments that use the body’s immune system to fight cancer more effectively, with a mission to provide new hope to patients facing challenging diagnoses. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, announced today that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM) has been successfully dosed at the Cleveland Clinic in Ohio.
